November 18, 2014
This manuscript outlines the first mathematical model that explicitly models the contribution of relapsing infections to P. vivax transmission. This model has since served as the basis of more advanced models investigating both the effect of different intervention on P. vivax transmission and evolutionary advantages of different relapse phenotypes.
September 9, 2014
This study standardised protective immune responses across multiple populations to identify biomarkers of protective vivax immunity across populations of varying malaria transmission.
September 8, 2014
A meta-analysis of >191 clinical trials highlighting the complexity of defining P. vivax antimalarial efficacy. The paper demonstrates that the extent of chloroquine resistant P. vivax is far greater than previously appreciated
Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs
September 1, 2014
Our invited review highlighted that current pharmacokinetic-pharmacodynamic models exclude important factors such as host immunity and complexities of drug action. We highlighted a lack of statistical rigour in parameter estimation.
Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria
July 1, 2014
This study demonstrated than human antibodies to merozoites promote opsonic phagocytosis by monocytes, which is was associated with protective immunity to malaria in Africa children. The acquisition and boosting of these antibodies was defined.
May 5, 2014
In Malawi and Papua New Guinea, maternal antibodies fell as malaria transmission declined, but rates of fall differed between different types of malaria antibody response.
Malaria burden and control in Bangladesh and prospects for elimination: an epidemiological and economic assessment
February 1, 2014
This original research quantifies the malaria burden and programmatic costs of malaria elimination in Bangladesh.
Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy
January 17, 2014
Background Artemisinin combination therapy (ACT) is recommended for the treatment of multidrug resistant malaria in the second and third trimesters…
Major burden of severe anemia from non-falciparum malaria species in southern Papua: A hospital-based surveillance study
December 17, 2013
This paper highlights the central role of anaemia in the aetiology of severe vivax malaria.
Low antibody levels to pregnancy-specific malaria antigens and heightened cytokine responses associated with severe malaria in pregnancy
November 25, 2013
Sudanese pregnant women with severe malaria had low levels of pregnancy-specific antibody suggesting low immunity, and had high blood cytokine levels. Lack of immunity may predispose to severe pregnancy malaria.